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Prostate cancer is the most common malignancy in elderly men
and is often complicated by osteosclerotic metastases. Bone
scintigraphy is commonly used to assess the extent of bone metas-
tases; its use is limited in monitoring of treatment efficacy because
it is an expensive, time-consuming technique that does not reflect
the rapid skeletal response to therapy (Coleman, 1998). The bone
scan flare response following successful therapy also reduces the
value of bone scanning in the early monitoring of treatment in
prostate cancer (Pollen et al, 1984). The serum level of prostate-
specific antigen is the most sensitive index of disease progression
in most but not all patients, but does not reflect the effects of
palliative treatments such as bisphosphonates for bone metastases
in patients that escape from antihormonal therapy.
The marked increase of osteoblastic activity in patients with
osteosclerotic metastases is reflected by increased levels of serum
total and bone-specific alkaline phosphatase (Pecherstorfer et al,
1995; Lorente et al, 1996). There is, however, biochemical
(Myamoto et al, 1994, Sano et al, 1994; Kylmala et al, 1995;
Berruti et al, 1996; Ikeda et al, 1996; Takeuchi et al, 1996; Maeda
et al, 1997; Nguyen-Pamart et al, 1997, Pelger et al, 1998) and
histological (Urwin et al, 1985; Clarke et al, 1991) evidence of
increased bone resorption in these patients even in the absence of
overt osteolytic bone metastases. This increased bone resorption is
of clinical relevance as it is the rationale for using bisphospho-
nates, a palliative treatment that has been shown to reduce bone
pain in patients with progressive metastatic prostate cancer who no
longer respond to hormonal therapy (Adami et al, 1985; Carey and
Lippert, 1988; Clarke et al, 1992; Kylmala et al, 1993, Taube et al,
1994; Pelger et al, 1998).
In this study we assessed the level of bone resorption in patients
with osteosclerotic metastases from prostate cancer before and
after bisphosphonate treatment by using new sensitive and specific
biochemical markers of bone resorption including a serum assay
for type I collagen C-telopeptide breakdown products; and values
were compared to those of bone formation markers.
PATIENTS AND METHODS
Forty-eight patients with carcinoma of the prostate (age 71.7 ± 9.6
years, mean ± 1 s.d.) and nine with benign prostatic hyperplasia
(BHP) (age 69.8 ± 4.2 years) were enrolled. All patients with
cancer had a prostatic biopsy and tissue diagnosis of adenocarci-
noma. Bone involvement and its extent was evaluated by bone
scintigraphy using Technetium-99m labelled methylene bisphos-
phonate. When bone metastases were suspected, confirmation was
obtained with standard radiographs, computerized tomography
(CT) and/or magnetic resonance imaging. The metastatic load in
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Summary Although increased bone formation is a prominent feature of patients with osteosclerotic metastases from prostate cancer, there is
also some evidence for increased bone resorption. The aim of this study was to compare the clinical utility of new bone resorption markers to
that of bone formation in patients with bone metastases from prostate cancer before and after bisphosphonate treatment. Thirty-nine patients
with prostate cancer and bone metastasis, nine patients with prostate cancer without bone metastases, nine patients with benign prostatic
hyperplasia and 355 healthy age-matched men were included. Urinary non-isomerized (a CTX) and b isomerized (b CTX) type I collagen 
C-telopeptides (CTX) and a new assay for serum CTX were used to assess bone resorption. Bone formation was determined by serum
osteocalcin, serum total (T-ALP) and bone (BAP) alkaline phosphatase and serum type I collagen C-terminal propeptide (PICP). Fourteen
patients with bone metastases were also evaluated 15 days after a single injection of the bisphosphonate pamidronate (120 mg). Levels of all
bone formation and bone resorption markers were significantly (P < 0.006–0.0001) higher in patients with prostate cancer and bone
metastasis than in patients with benign prostatic hyperplasia, patients with prostate cancer without bone metastases and healthy controls. In
patients with bone metastases the median was increased by 67% for serum osteocalcin, 128% for T-ALP, 138% for BAP, 79% for PICP, 220%
for urinary a CTX, 149% for urinary b CTX and 214% for serum CTX. After bisphosphonate treatment all three resorption markers significantly
decreased by an average of 65% (P = 0.001), 71% (P = 0.0010) and 61% (P = 0.0015) for urinary a CTX, urinary b CTX and serum CTX,
respectively, whereas no significant change was observed for any bone formation markers. Patients with prostate cancer and bone
metastases exhibit a marked increase in bone resorption, which decreases within a few days of treatment with pamidronate. These findings
suggest that these new resorption markers may be useful for the management of these patients. © 2000 Cancer Research Campaign
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graded using the scoring and stratification proposed by Soloway et
al (1988) in a subset of 32 patients with prostate cancer. Patients
were classified into two groups: score < 2 (i.e. 0 and 1) corre-
sponding to fewer than six malignant bone lesions; score ³ 2 (from
2 to 4) corresponding to six and more lesions. Among the subjects
with prostate cancer, 39 had proven bone metastases (age 71.8 ±
9.6 years), whereas nine (age 71.1 ± 9.8 years) had no detectable
metastatic diseases. The nine patients with BPH had no previous
history of malignancy and the biopsy specimen did not reveal any
evidence of cancer. Forty-eight out of the 57 patients had no
previous treatment for their prostate disease. Five subjects with
skeletal metastases had undergone orchidectomy 4–56 months
before the study (23 ± 4 months) and two had a previous hormonal
therapy (cyproterone acetate for 3 months, flutamide for 8
months). Fourteen patients with endocrine-resistant bone metas-
tases were also assessed 15 days after a single intravenous injection
of the bisphosphonate pamidronate (120 mg). All these 14 patients
had apparently sclerotic disease with no radiographical evidence
of lytic lesions. None of the patients had renal insufficiency.
Bone marker levels in patients with prostate cancer and BPH
were compared to those of 355 healthy age-matched men (mean
age 70.1 ± 5.9 years: 51–85 years) taken from a large population-
based cohort involved in a prospective study on the determinants
of bone loss in men (MINOS study). None of the controls had a
disease or treatment that may affect bone metabolism. These
studies were approved by the local ethical committee and informed
consent was obtained from all participants.
Fasting serum and 2-h urine samples were collected in all
patients for measuring biochemical markers of bone turnover.
Bone markers
Markers of bone formation included serum total osteocalcin
(ELSA-OSTEO, Cis biointernational, Gif/Yvette, France) (Garnero
et al, 1992), total alkaline phosphatase activity (T-ALP) measured
by a colorimetric method (Alkaline phosphatase® AMP-buffer,
Boehringer, Germany), serum bone-specific alkaline phosphatase
(BAP, Alkaphase B, Metra Biosystems, Mountain View, CA,
USA) (Gomez et al, 1995) and serum type I collagen C-terminal
propeptide (PICP, Prolagen-C™, MetraBiosystems®, Palo Alto,
CA, USA) (Winterbottom et al, 1993). Bone resorption was
assessed by measuring the urinary excretion of non-isomerized (a)
and b isomerized (b) C-telopeptides of type I collagen (CTX) by
alpha Crosslaps RIA (Osteometer Biotech, Herlev, Denmark) 
and Crosslaps enzyme-linked immunosorbant assay (ELISA) (CIS
Biointernational, Gif/Yvette, France) respectively (Bonde et 
al, 1994, 1996). We also measured the serum concentration 
of CTX using a new immunoassay (Serum Crosslaps 
one-step™, CIS Biointernational®, Gif/Yvette, France). This
serum resorption marker assay uses two monoclonal antibodies
raised against a synthetic peptide with an amino acid sequence
specific for a part of the C-telopeptide of the a 1 chain of type I
collagen (Glu-Lys-Ala-His-bAsp-Gly-Gly-Arg) (Bonde et al,
1997; Rosenquist et al, 1998). Intra- and interassay CVs are lower
than 5 and 8% respectively and the sensitivity is 0.15 nmol/l.–1
Statistical analyses
Significance of the difference between groups was assessed using
non-parametric tests (Mann–Whitney rank test or Kruskall–Wallis
tests) where the a risk was corrected according to Bonferroni’s
procedure. Relationships between markers were assessed by
Spearman (rank) correlation analysis. The effect of bisphospho-
nate treatment was assessed by the non-parametric Wilcoxon
paired test.
RESULTS
All bone turnover markers were significantly higher in patients
with bone metastases from prostate cancer compared to healthy
age-matched controls, localized prostate cancer and patients with
BPH (Table 1). No significant difference was found between
healthy men, patients with BPH and those with localized prostate
cancer. For bone formation, T-ALP, BAP and PICP provided
similar associations with bone metastases, whereas serum osteo-
calcin was less increased. Indeed, the sensitivity defined as the
proportion of patients with bone metastases exhibiting bone
marker levels higher than the mean + 2 standard deviations (s.d.)
of normals was 62% for T-ALP, 62% for BAP, 60% for PICP and
only 43% for osteocalcin (Figure 1). No patient with BPH or local-
ized prostate cancer demonstrated increased T-ALP, BAP and
PICP levels. The three resorption markers demonstrated a similar
performance in the detection of bone metastases with a sensitivity
of 61%, 53% and 64% for urinary a CTX, urinary b CTX and
serum CTX respectively (Figure 1). In patients with bone metas-
tases, we found significant correlation between all markers investi-
gated with, however, lowest values with serum osteocalcin (Table
2). When patients with prostate cancer were divided in two groups
according to the bone metastatic load, higher levels of all bone
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Table 1 Markers of bone turnover in controls and patients with prostate diseases. Results are shown as median (interquartile range)
Healthy controls BPHa PC. M–b PC. M+c Pe
(n = 355) n = 9) (n = 9) (n = 39)
Osteocalcin (ng ml–1) 17.8 (7.8) 18.2 (9.8) 16.5 (11.7) 29.8d (28.6) 0.005
T-ALP (IU l–1) 50 (21) 45 (18) 38 (10) 114d (192) < 0.0001
BAP (ng ml–1) 16.2 (6.8) 13.5 (6.7) 8.7 (3.6) 38.5d (105) < 0.0001
PICP (ng ml–1) 94 (33) 74 (33) 61 (33) 168 (121) < 0.0001
Urinary a CTX (mg mmol–1 Cr) 194 (140) 197 (253) 184 (430) 621d (1165) 0.0056
Urinary b CTX (mg mmol–1 Cr) 146 (90) 120 (188) 89 (214) 363d (650) 0.0056
Serum CTX (nmol l–1) 2.2 (1.3) 2.7 (2.3) 2.5 (3.5) 6.9d (8.4) 0.0008
aBenign prostate hyperplasia patients; bpatients with prostate cancer without bone metastases; cpatients with prostate cancer with bone
metastases. No significant difference for any marker between healthy controls, BPH and PC. M–. d P < 0.0001 vs healthy controls. 
eComparison between PC. M + and BPH+PC. M–.860 P Garnero et al
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nformation and bone resorption markers were observed in those
with a Soloway score ³ 2 compared to those with a score < 2, with
however no significant difference for the two urinary resorption
markers (Table 3).
The effect of bisphosphonate treatment was assessed in a subset
of the patients with bone metastases. A single injection of
pamidronate induced a decrease of the three resorption markers in
all patients, with a mean fall of 60–70%. Before treatment,
70–80% of patients had levels above the upper limit of the normal
range, whereas only 15–35% had increased levels 15 days after the
injection of bisphosphonate (Figure 2). No significant change in
osteocalcin (–8 ± 18%, P = 0.35); T-ALP (–2 ± 23%, P = 0.73),
BAP (+ 3 ± 21%, P = 0.75) or PICP (–12 ± 28%, P = 0.20) was
observed after 15 days of treatment (Figure 2).
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Table 2 Correction between biochemical markers of bone turnover in patients with bone metastases from prostate cancer
Osteocalcin T-ALP BAP PICP Urinary a CTX Urinary b CTX
T-ALP 0.43 (0.01)
BAP 0.36 (0.03) 0.98 (<0.0001)
PICP 0.46 (0.007) 0.79 (< 0.0001) 0.82 (< 0.0001)
Urinary a CTX 0.46 (0.005) 0.56 (0.0012) 0.59 (0.0003) 0.57 (0.0001)
Urinary b CTX 0.45 (0.007) 0.52 (0.003) 0.51 (0.002) 0.51 (0.004) 0.94 (< 0.0001)
Serum CTX 0.38 (0.02) 0.65 (0.0002) 0.66 (< 0.0001) 0.64 (0.0002) 0.73 (< 0.0001) 0.67 (< 0.0001)
Results are shown as the Spearman correlation coefficient (significance level).
Table 3 Bone turnover and bone metastatic load in patients with prostate cancer
Soloway score
< 2 ³ 2 P
n = 14 n = 18
Osteocalcin (ng ml–1) 20.7 (9.9) 28.5 (36.3) 0.03
T-ALP (IU l–1) 41 (21) 108 (196) 0.0003
BAP (ng ml–1) 9.3 (6.0) 40.6 (114) <0.0001
PICP (ng ml–1) 70 (44) 182 (191) 0.0004
Urinary a CTX (mg mmol–1 Cr) 222 (477) 467 (1324) 0.11
Urinary b CTX (mg mmol–1 Cr) 101 (258) 194 (549) 0.26
Serum CTX (nmol l–1) 3.9 (3.8) 8.4 (10.8) 0.01
The Soloway score was assessed by isotopic bone scintigaphy. Score < 2 was defined by
fewer than 6 bone metastases and score ³ 2 by 6 or more bone metastases. Results are
shown as median (interquartile range).
Serum
bone alkaline
phosphatase
Serum CTX Urinary b CTX
mg mmol
-1 Cr
Urinary a CTX
mg mmol
-1 Cr nmol l-1 IU I-1
Before           After Before             After Before             After Before               After
4000
3500
3000
2500
2000
1500
1000
500
0
4000
3500
3000
2500
2000
1500
1000
500
0
400
300
200
100
0
40
30
–65%
P=0.0010
–71%
P=0.0010
–61%
P=0.0015
+3%
P=0.75
 
15
14
13
12
11
0
1
2
3
4
5
6
7
8
9
10
Figure 2 Response of 3 bone resorption markers and serum bone alkaline phosphatase to bisphosphonate treatment in patients with prostate cancer with
bone metastases. Levels of each marker are shown before treatment and 15 days after a single i.v. of pamidronate (120 mg). The dotted line represents the
upper limit of the normal range as defined in Figure 1DISCUSSION
In this study, we found that patients with bone metastases from
prostate cancer are characterized by an increased bone formation
and by a marked increase in bone resorption as assessed by several
biochemical markers of bone resorption, including a new assay for
serum type I collagen fragments. Markers of bone resorption, but
not those of bone formation, were significantly reduced within 15
days after a treatment with bisphosphonate.
Amongst the bone formation markers, our study confirms the
higher association of serum T-ALP, BAP and PICP over serum
osteocalcin with bone metastases (Koizumi et al, 1997; Nakashima
et al, 1997; Yoshida et al, 1997). Of interest, T-ALP, which is still
the parameter most widely used for assessing bone metastases, was
as sensitive as BAP, suggesting that this non-specific bone turnover
marker is a valuable index of bone formation in this condition.
However, others reported a higher diagnostic value of BAP
compared to T-ALP especially for stratifying the degree of bone
metastases (Akimoto et al, 1998). The reasons for the lower sensi-
tivity of serum osteocalcin are unclear, but this situation is reminis-
cent of that found in Paget’s disease of bone (Delmas et al, 1986),
which, like prostate cancer, is characterized by a marked increase
of bone turnover with the formation of newly woven bone. After
secretion by the osteoblastic cells, part of the newly synthesized
osteocalcin is captured by bone matrix and part is released in the
circulation. In Paget’s disease, the low sensitivity of serum osteo-
calcin has been suggested to be related to an increased uptake of
newly synthesized osteocalcin by the woven bone, resulting in a
decrease of the fraction released into the circulation. This may also
be related to the involvement of osteoblasts at different stages of
differentiation. Indeed, PICP is believed to be a marker of the early
or proliferation phase, BAP a marker of matrix maturation phase
and osteocalcin a marker of late bone formation.
Most of the resorption marker assays are currently using urine
samples. Urinary resorption markers have several limitations,
including the need for control of sampling time and correction for
urinary creatinine, and a large within patient variability (Garnero
et al, 1994; Hannon et al, 1998). Urinary collection is, moreover,
often cumbersome in clinical practice. A serum-based assay
measuring carboxyterminal type I collagen telopeptide (ICTP) has
been developed (Risteli et al, 1993) and increased ICTP levels
have been reported in prostate cancer patients with bone metas-
tases (Kylmala et al, 1995; Yoshida et al, 1997; Akimoto et al,
1998). However, the tissue specificity and the clinical significance
of serum ICTP levels are still unclear. In particular, ICTP levels
increase after treatment with anabolic steroids, which are believed
to decrease bone resorption and to stimulate collagen synthesis
(Hassager et al, 1994). Thus, ICTP appears to be more a marker of
collagen turnover than of bone resorption.
In the present study we used a new serum bone resorption
marker that has been shown to specifically reflect bone resorption
(Bonde et al, 1997; Rosenquist et al, 1998). This is the first study
demonstrating its utility for monitoring osteosclerotic metastases
from prostate cancer. The sensitivity of serum CTX to detect bone
metastases compares very well with that of urinary measurements
of  a and  b CTX and with those previously reported for the
conventional, but cumbersome high performance liquid chro-
matography measurement of total excretion of pyridinoline and
deoxypyridinoline (Myamoto et al, 1994; Sano et al, 1994;
Takeuchi et al, 1996). Interestingly, serum CTX levels correlated
with the metastatic load in bone as assessed by the Soloway score
in contrast to the two urinary resorption markers. These data
suggest that this new serum CTX assay represents an adequate
alternative to the urinary resorption markers for assessing bone
involvement in prostate cancer. Serum CTX appears to reflect
more accurately the extent of bone disease, probably due to the
lower precision error of serum compared to urinary measurements
(Christgau et al, 1997). Nevertheless, because the sensitivity for all
markers investigated ranged from 53 to 64%, biochemical markers
are likely to be of little help in the diagnosis of secondary bone
involvement in prostate cancer.
Bisphosphonates, which are potent inhibitors of bone resorp-
tion, are an important adjuvant treatment for the management of
metastatic bone disease. Bisphosphonates are the treatment of
choice for hypercalcaemia of malignancy (Body et al, 1996) and
have been shown to reduce skeletal complications in multiple
myeloma (Berenson et al, 1996) and breast cancer (Hortobayi et
al, 1996). They relieve metastatic bone pain caused by a variety of
solid tumours, including prostate, with a consequent improvement
in quality of life (Adami et al, 1985; Carey and Lippert, 1988;
Coleman et al, 1996; Pelger et al, 1998). Interestingly, it has been
suggested that the pretreatment levels, the magnitude of the
change of the decreases under treatment and the levels reached
after treatment of some urinary resorption markers are predictive
of the efficacy of pamidronate in reducing pain in normocalcaemic
carcinoma patients (Vinholes et al, 1996, 1997; Adami et al,
1997), suggesting that these markers may be useful to monitor the
efficacy of bisphosphonate treatment in patients with bone metas-
tases.
One of the main criteria to judge the clinical utility of bone
markers is the time-course and magnitude of the response under
treatment. Fifteen days after treatment with bisphosphonate none
of the four markers of bone formation decreased contrasting with
the significant reduction of the bone resorption markers. Because
the renal clearance of osteocalcin and the hepatic clearance of
BAP and PICP are very rapid with a half-life lower than 6 min for
all three markers (Price et al, 1981; Young et al, 1984; Smedsrod 
et al, 1990; Blom et al, 1998), if pamidronate has decreased the
release of these markers from bone to blood, a significant decrease
in their circulating levels would also has been observed after 15
days. More likely, the absence of decrease of bone formation
markers results from the direct inhibitory action of the amino-
bisphosphonate pamidronate on bone resorption, followed by an
indirect decrease in bone formation through the operation of the
coupling mechanism. This short-term response is similar to that
previously found in patients with Paget’s disease of bone treated
by pamidronate (Uebelhart et al, 1990) and more recently in
patients with prostate cancer treated with another bisphosphonate,
olpadronate (Pelger et al, 1998).
We observed a 60–70% decrease of the levels of bone resorption
markers including serum CTX after treatment with bisphospho-
nate, i.e. a magnitude similar to that reported by Vinholes et al
(1997) for urinary NTX using a similar treatment protocol. It
should be pointed out, however, that in a large proportion of
patents with high levels to start with, the biochemical markers of
bone resorption remained increased after treatment. Similar results
have been observed when bone resorption was assessed by urinary
hydroxyproline and this was ascribed to the contribution of
metastatic involvement of soft tissues to the excess of hydroxy-
proline excretion. The inability of a single dose of pamidronate to
862 P Garnero et al
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normalize levels of three bone-specific resorption markers suggest
that more intensive schedules, higher doses or more potent bis-
phosphonates will be required to normalize bone turnover in most
patients.
The three different biochemical markers of bone resorption used
in this study recognize fragments of the C-telopeptide of the alpha
1 chain of type I collagen and all of them used antibodies raised
against an amino acid sequence containing a lysine involved in the
cross-linking of collagen molecules. Although, a CTX and b CTX
assays could at least theoretically detect degradation products
from newly-synthesized molecules that have not participated in
fibre formation, it has been shown that the majority of urinary
fragments detected by these two assays are linked by pyridinoline,
deoxypyridinoline or a non-fluorescent cross-link (Fledelius et al,
1997). Since the two monoclonal antibodies used in the serum
CTX assay must bind to the same antigen simultaneously for
detection to occur, it is a prerequisite that the type I collagen frag-
ments measured are cross-linked (Rosenquist et al, 1998). Thus,
all three assays are likely to reflect mainly the degradation of type
I collagen molecules, which have participated in fibre formation.
However, the different assays differ by their ability to detect the
b isomerization process which is a post-translational modification
believed to be associated with ageing of proteins. Indeed, the
urinary a CTX assay recognizes non-isomerized fragments,
whereas urinary b CTX assay and serum CTX recognize b isomer-
ized fragments and thus are likely to reflect degradation of aged
bone matrix. We previously found that in patients with Paget’s
disease of bone, the increase of urinary a CTX was much more
important than that of b CTX because the woven bone character-
izing these patients is comprised mainly of non-isomerized type I
collagen molecules as indicated by immunohistochemistry
(Garnero et al, 1997). Because patients with bone metastases from
prostate cancer, like patients with Paget’s disease, are character-
ized by a marked increase of bone turnover in localized area of the
skeleton, we could expect a higher increase of a CTX compared to
b CTX. Such a hypothesis has been raised recently by Engler et al
(1998) to explain the better sensitivity of serum ICTP – a marker
believed to detect both non-isomerized and b isomerized frag-
ments – compared to urinary b CTX for detecting osteolytic
metastases and the difference in their response after treatment with
pamidronate. In contrast in our study, we found similar increases
over controls and response to treatment of urinary a CTX, urinary
b CTX and serum CTX, suggesting that in our cohort of prostate
cancer patients the pattern of b isomerization of type I collagen
was not altered. There are several reasons that could explain these
differences. In the study of Engler et al (1998) most of the patients
had bone metastases from breast involvement and only 19 from
prostate cancer. They observed the effect of bisphosphonate treat-
ment after 28 days compared to 15 days in our study. According to
our data in patients with Paget’s disease of bone, short-term treat-
ment with bisphosphonate induces similar decreases of non-
isomerized and b isomerized CTX, whereas with advancing time
differences between the two markers occur (Garnero et al, 1998).
In addition as pointed out before, because ICTP is not a specific
marker of bone resorption, its large increase in untreated cancer
patients and the absence of significant decrease under bisphospho-
nate observed by Engler et al (1998) could also result in part from
the contribution of soft tissues to serum ICTP levels.
Our study has some limitations. Patients were not separated
according to the type of metastases, i.e. purely sclerotic or mixed.
Thus, we could not investigate whether or not markers reflecting
the degradation of non-isomerized and b isomerized CTX could
give different information in these two groups; further studies in
this area are required. We did not investigate the value of biochem-
ical markers to predict the efficacy of bisphosphonate to reduce
bone pain – a relationship that we previously reported for other
markers (Vinholes et al, 1996, 1997) – although just 2-week time
points is probably too few to adequately address this issue.
In conclusion, using a panel of recently developed markers of
bone resorption, including a new serum assay for type I collagen
breakdown products, we found that patients with prostate cancer
are characterized by a marked increase of bone resorption which
decreases within 2 weeks of treatment with high dose
pamidronate, whereas no significant change was observed for
markers of bone formation. These data suggest that new assays for
urinary and serum CTX may be useful to monitor its efficacy.
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